News, reviews and podcasts from annual scientific meetings and symposiums around the world.
ASCO 2025: Vepdegestrant could extend progression-free survival for some people with ESR1-mutated advanced breast cancer
Results from VERITAC-2, the first global phase 3 clinical trial of a PROTAC, a targeted…